Clinical Study

Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy

Table 3

Partial correlations of TBS prior to adalimumab (baseline) and after 6 months of TNF-α blockade, in 29 patients with moderate to-severe psoriasis.

VariableTrabecular bone score (TBS)
Baseline6 months

HOMA−0.2030.32−0.4450.02
QUICKI0.2400.240.4970.01
Systolic BP−0.4240.03−0.4070.04
Diastolic BP−0.4550.02−0.4550.03
Total cholesterol−0.0970.64−0.0220.92
HDL cholesterol0.3450.080.2760.17
LDL cholesterol−0.2200.28−0.1200.56
Triglycerides−0.1760.39−0.1300.53
Non-HDL cholesterol−0.2460.23−0.1410.49
Apo-A10.1890.370.2030.32
Apo-B−0.1900.36−0.1450.48
Lpa0.1000.630.2160.30
Castelli index−0.4110.04−0.3290.10
Apo-B/Apo-A1−0.2950.15−0.0600.77
Homocysteine0.1790.430.0550.78
ESR0.0930.65−0.0240.91
HbA1c−0.3300.090.0250.91
Insulin−0.2140.29−0.4770.01
Glucose−0.2270.27−0.1800.38
Creatinine0.2920.150.0040.98
hs-CRP−0.4240.03−0.4830.01
Weight−0.5320.005−0.6870.0001
BMI−0.5990.001−0.7640.0001
Waist perimeter−0.5780.002−0.6820.0001
BSA0.1460.47−0.1470.48
PASI−0.0100.96−0.3050.13
NAPSI hands0.0230.91−0.1840.39
PGA psoriasis−0.1300.53−0.2850.17
PASE total score−0.1050.61−0.0280.89
PASE functional−0.1250.54−0.0790.70
PASE symptoms−0.0800.700.0170.94
Adiponectin−0.0770.71−0.4890.01
Leptin−0.3200.11−0.4790.01
Resistin−0.3050.13−0.1990.33
Visfatin−0.1260.54−0.0350.86
Fat mass (%)−0.4440.02−0.5600.003

Adjusted for sex, age at the study onset, and disease duration.
Significant results are highlighted in bold.